scholarly article | Q13442814 |
P356 | DOI | 10.1016/J.EJCA.2015.09.018 |
P8608 | Fatcat ID | release_6mjrokjiyfcx7edn3w3jed4dk4 |
P698 | PubMed publication ID | 26693898 |
P5875 | ResearchGate publication ID | 286904328 |
P50 | author | Jeong Hoon Lee | Q39185931 |
Hwoon-Yong Jung | Q57766691 | ||
P2093 | author name string | Yoon-Koo Kang | |
Young Soo Park | |||
Sook Ryun Park | |||
Baek-Yeol Ryoo | |||
Chang Gok Woo | |||
Min-Hee Ryu | |||
Gin Hyug Lee | |||
P304 | page(s) | 42-50 | |
P577 | publication date | 2015-12-13 | |
P1433 | published in | European Journal of Cancer | Q332260 |
P1476 | title | Extra-gain of HER2-positive cases through HER2 reassessment in primary and metastatic sites in advanced gastric cancer with initially HER2-negative primary tumours: Results of GASTric cancer HER2 reassessment study 1 (GASTHER1). | |
P478 | volume | 53 |
Q40619773 | Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications |
Q87944884 | Clinicopathological features and endoscopic findings of HER2-positive gastric cancer |
Q92905048 | Correlation of HER2, MDM2, c-MYC, c-MET, and TP53 Copy Number Alterations in Circulating Tumor Cells with Tissue in Gastric Cancer Patients: A Pilot Study |
Q64076253 | Detection of (HER2) Gene Amplification Events in Cell-Free DNA and Response to Anti-HER2 Agents in a Large Asian Cancer Patient Cohort |
Q50642054 | Detection of HER2 Amplification in Circulating Tumor Cells of HER2-Negative Gastric Cancer Patients. |
Q50433440 | Discordance Rate of HER2 Status in Primary Gastric Cancer and Synchronous Lymph Node Metastases: Its Impact on Therapeutic Decision and Clinical Management |
Q93059944 | Discordance in HER2 status between primary gastric adenocarcinoma tumors and cells from the corresponding malignant effusions |
Q92644985 | Elevated level of Vav1 was correlated with advanced biological behavior and poor prognosis in patients with gastric cancer |
Q89683058 | Emerging Targeted Therapies for HER2 Positive Gastric Cancer That Can Overcome Trastuzumab Resistance |
Q99622843 | Gastric cancer |
Q46129222 | Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma. |
Q39080349 | HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. |
Q26741253 | HER2 heterogeneity in gastric/gastroesophageal cancers: From benchside to practice |
Q92685589 | HER2 heterogeneity is a poor prognosticator for HER2-positive gastric cancer |
Q51541370 | HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research. |
Q39174711 | HER2 testing in gastric cancer: results of a German expert meeting |
Q50160878 | Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2-positive gastric cancer patients |
Q58553403 | Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3) |
Q28077666 | Trastuzumab in the management of gastroesophageal cancer: patient selection and perspectives |
Q55039208 | Using antibody directed phototherapy to target oesophageal adenocarcinoma with heterogeneous HER2 expression. |
Q53073585 | [HER2 testing in gastric cancer : Results of a meeting of German experts]. |
Search more.